

| Prescriber Information | | | | | | | | | | | | |
|---|----------------------------|--|---|--|---|---|---------------------------|------------------------------|------------------------|------------------------|-------------------|--|
| Prescriber Name: | | | | | MD | DO | NP | PA | NPI: | | | |
| Office Contact: | | | | | Practice Name / Collaborating MD: | | | | | | | |
| Address: | | | City: | | | State: | | Zip: | | | | |
| Phone: | | Fax: | | | | | | | | | | |
| Patient Information • PLEASE SEND COPY OF INSURANCE CARD | | | | | | | | | | | | |
| Patients Name: | | | Last 4 Digits of SS#: | | DOB: / / | | Sex: M F | | Weight: | Height: | Diabetic? Y N | |
| Office Contact: | | | | | Practice Name / Collaborating MD: | | | | | | | |
| Address: | | | City: | | | State: | | Zip: | | | | |
| Home Phone: | | Work/Cell: | | HIPPA Contact: | | | Emergency #: | | | | | |
| Interpreter Needed? Y N | | Allergies: Y N If Yes, list allergies: | | | | | | | | | | |
| Insurance Information | | | | | | | | | | | | |
| Primary Insurance: | | | Policy ID: | | Group #: | | BIN: | | PCN: | | | |
| Policyholder Name: | | | | | Policyholder DOB: / / | | | | | | | |
| Clinical Information • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES | | | | | | | | | | | | |
| ICD-10/Diagnosis Code: | Psoriasis Vulgaris (L40.0) | Other Psoriasis (L40.8) | Psoriasis unspecified (L40.9) | Psoriatic Arthritis (L40.5) | Hidradenitis Suppurativa (L73.2) | Chronic Urticaria (L50.8) | Atopic Dermatitis (L20.9) | Basal cell carcinoma (C44.) | TB/PDD Test Given: Y N | Date of Neg. Test: / / | HBV Positive? Y N | If Yes, is patent currently treated? Y N |
| Prior Treatment? Y N (Provide Information Below) | | BSA Affected (%): | | Affected Areas: Palms Soles Head Neck Genitalia Other: | | | | | | | | |
| Prior Therapy: | | | | Reason for Discontinuation of Therapy: | | | | Approx. Start Date: / / | | Approx. End Date: / / | | |
| Comorbidities: | | | Concomitant Medications: | | | | Allergies: NKDA | | Other: | | | |
| Prescription Information | | | | | | | | | | | | |
| Medication | | Quantity/Dose | | | Sig | | | Refills | | | | |
| CIMZIA® PFS Vials | | 1 starter kit (6x200mg/mL) | | | Starter Dose: Inject 400mg SQ at weeks 0, 2 and 4 | | | No Refills | | | | |
| | | 1 carton (2x200mg/mL) 2 cartons (4x200mg/mL) | | | Maintenance Dose: Inject 400mg SQ every 4 weeks Inject 200mg SQ every 2 weeks Inject 400mg SQ every other week (plaque psoriasis only) Inject 200mg SQ every other week | | | | | | | |
| COSENTYX® <i>*Pediatrics (age 6 & older)</i> | | 4 cartons (4x75mg/0.5ml) PFS 4 cartons (4x150mg/ml) PFS 4 cartons (4x150mg/ml) PEN | | | Starter Dose: Weight < 50kg: Inject 75mg SQ at weeks 0, 1, 2, and 3 Weight ≥ 50kg: Inject 150mg SQ at weeks 0, 1, 2, and 3 | | | No Refills | | | | |
| | | 1 carton (1x75mg/0.5ml) PFS 1 carton (1x150mg/ml) PFS 1 carton (1x150mg/ml) PEN | | | Maintenance Dose: Weight < 50kg: Inject 75mg SQ every 4 weeks beginning on Day 29 Weight ≥ 50kg: Inject 150mg SQ every 4 weeks beginning on Day 29 | | | | | | | |
| COSENTYX® <i>*Adults</i> PFS Sensoready® Pen | | 4 cartons (8x150mg/mL) 4 cartons (4x150mg/mL) | | | Starter Dose: Inject 300 mg SQ at weeks 0, 1, 2, and 3 Starter Dose: Inject 150 mg SQ at weeks 0, 1, 2, and 3 | | | No Refills | | | | |
| | | 1 carton (2x150mg/mL) 1 carton (1x150mg/mL) | | | Maintenance Dose: Inject 300 mg SQ every 4 weeks beginning on Day 29 Maintenance Dose: Inject 150 mg SQ every 4 weeks beginning on Day 29 | | | | | | | |
| DUPIXENT® <i>*Pediatrics (age 6 & older)</i> PFS Pen <i>*Dupixent pens only for use in adolescents aged 12 or older</i> | | 1 carton (2x200mg/1.14mL) 1 carton (2x300mg/2mL) | | | Starter Dose: Weight 15-29kg: Inject 600mg SQ at week 0. Begin maintenance dose at week 4 Weight 30-59kg: Inject 400mg SQ at week 0. Begin maintenance dose at week 2 Weight ≥ 60kg: Inject 600mg SQ at week 0. Begin maintenance dose at week 2 | | | No Refills | | | | |
| | | 1 carton (2x200mg/1.14mL) 1 carton (2x300mg/2mL) | | | Maintenance Dose: Weight 15-29kg: Inject 300mg SQ every 4 weeks Weight 30-59kg: Inject 200mg SQ every 2 weeks Weight ≥ 60kg: Inject 300mg SQ every 2 weeks | | | | | | | |
| DUPIXENT® <i>*Adults</i> PFS Pen | | 1 carton (2x300mg/2mL) | | | Starter Dose: Inject 600mg SQ at week 0. Begin maintenance dose at week 2 | | | No Refills | | | | |
| | | 1 carton (2x300mg/2mL) | | | Maintenance Dose: Inject 300mg SQ every 2 weeks | | | | | | | |
| Injection Training | | | | | | | | | | | | |
| Patient received injection training | | | Prescriber's office to provide injection training | | | Meijer to coordinate injection training | | | | | | |
| By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies. | | | | | | | | | | | | |
| Prescriber Signature | | | Date | | Prescriber Signature | | | Date | | | | |

Substitution Permitted

Dispense as Written

If brand is required, please write "DAW" in the box to the right.